Hong-Fen Guo

2.8k total citations
50 papers, 2.0k citations indexed

About

Hong-Fen Guo is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Neurology. According to data from OpenAlex, Hong-Fen Guo has authored 50 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 27 papers in Radiology, Nuclear Medicine and Imaging and 18 papers in Neurology. Recurrent topics in Hong-Fen Guo's work include Monoclonal and Polyclonal Antibodies Research (22 papers), CAR-T cell therapy research (19 papers) and Neuroblastoma Research and Treatments (18 papers). Hong-Fen Guo is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), CAR-T cell therapy research (19 papers) and Neuroblastoma Research and Treatments (18 papers). Hong-Fen Guo collaborates with scholars based in United States, Japan and South Korea. Hong-Fen Guo's co-authors include Nai‐Kong V. Cheung, Irene Y. Cheung, Hong Xu, Cuiwen Tan, Michel Sadelain, Jean‐Baptiste Latouche, Anja Krause, Shakeel Modak, Steven M. Larson and Robert A. Ross and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Hong-Fen Guo

48 papers receiving 2.0k citations

Peers

Hong-Fen Guo
Syed R. Husain United States
S. D. Gillies United States
Jacek Gan United States
J. T. Kemshead United Kingdom
Chien‐Tsun Kuan United States
Charles N. Pegram United States
Sandrine Valsesia‐Wittmann France
Meng-Fen Wu United States
Peisheng Hu United States
Syed R. Husain United States
Hong-Fen Guo
Citations per year, relative to Hong-Fen Guo Hong-Fen Guo (= 1×) peers Syed R. Husain

Countries citing papers authored by Hong-Fen Guo

Since Specialization
Citations

This map shows the geographic impact of Hong-Fen Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong-Fen Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong-Fen Guo more than expected).

Fields of papers citing papers by Hong-Fen Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong-Fen Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong-Fen Guo. The network helps show where Hong-Fen Guo may publish in the future.

Co-authorship network of co-authors of Hong-Fen Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Hong-Fen Guo. A scholar is included among the top collaborators of Hong-Fen Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong-Fen Guo. Hong-Fen Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fung, Edward K., Sang Gyu Lee, Sébastien Monette, et al.. (2025). GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer. Theranostics. 15(13). 6274–6289. 2 indexed citations
2.
Jiang, Hua, Hong-Fen Guo, Maegan L. Capitano, et al.. (2025). Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway. Nature Communications. 16(1). 6369–6369. 1 indexed citations
3.
Guo, Hong-Fen, Fangjian Zhou, & Chengwei Zhou. (2023). MA04.04 A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC. Journal of Thoracic Oncology. 18(11). S110–S110. 1 indexed citations
4.
Park, Jeong A, et al.. (2023). Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. Journal for ImmunoTherapy of Cancer. 11(3). e006680–e006680. 31 indexed citations
5.
Hoseini, Sayed Shahabuddin, Hoa Tran, Yi Feng, et al.. (2021). T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. Journal for ImmunoTherapy of Cancer. 9(5). e002509–e002509. 7 indexed citations
6.
Chung, Sebastian, Darren R. Veach, Edward K. Fung, et al.. (2021). Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular Cancer Therapeutics. 21(1). 125–137. 11 indexed citations
7.
Hoseini, Sayed Shahabuddin, et al.. (2020). Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies. Journal for ImmunoTherapy of Cancer. 8(2). e001626–e001626. 9 indexed citations
8.
Wu, Zhihao, Hong-Fen Guo, Hong Xu, & Nai‐Kong V. Cheung. (2018). Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Molecular Cancer Therapeutics. 17(10). 2164–2175. 32 indexed citations
9.
Cheal, Sarah M., Hong Xu, Hong-Fen Guo, et al.. (2018). Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics. 8(18). 5106–5125. 28 indexed citations
10.
Cheal, Sarah M., Edward K. Fung, Mitesh Patel, et al.. (2017). Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of Nuclear Medicine. 58(11). 1735–1742. 32 indexed citations
11.
Xu, Hong, Hong-Fen Guo, Irene Y. Cheung, & Nai‐Kong V. Cheung. (2016). Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering. Cancer Immunology Research. 4(7). 631–638. 13 indexed citations
12.
Ross, Robert A., et al.. (2015). A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Research. 15(2). 419–426. 41 indexed citations
13.
Cheal, Sarah M., Hong Xu, Hong-Fen Guo, et al.. (2015). Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging. 43(5). 925–937. 33 indexed citations
14.
Ahmed, Mahiuddin, Ming Cheng, Qi Zhao, et al.. (2015). Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. Journal of Biological Chemistry. 290(50). 30018–30029. 85 indexed citations
15.
Xu, Hong, Ming Cheng, Hong-Fen Guo, et al.. (2014). Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody. Cancer Immunology Research. 3(3). 266–277. 70 indexed citations
16.
Cheal, Sarah M., Hong Xu, Hong-Fen Guo, et al.. (2014). Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex. Molecular Cancer Therapeutics. 13(7). 1803–1812. 45 indexed citations
17.
Zhang, Hanwen, Ruimin Huang, Nai‐Kong V. Cheung, et al.. (2014). Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [18F]-MFBG and 123I-MIBG. Clinical Cancer Research. 20(8). 2182–2191. 58 indexed citations
18.
19.
Spengler, Barbara A., et al.. (2004). Characteristics of Stem Cells from Human Neuroblastoma Cell Lines and in Tumors. Neoplasia. 6(6). 838–845. 183 indexed citations
20.
Cheung, Nai‐Kong V., Hong-Fen Guo, Shakeel Modak, & Irene Y. Cheung. (2002). Anti-Idiotypic Antibody as the Surrogate Antigen for Cloning scFv and its Fusion Proteins. PubMed. 21(6). 433–443. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Syed R. Husain Breakdown of academic impact, for papers by S. D. Gillies Breakdown of academic impact, for papers by Jacek Gan Breakdown of academic impact, for papers by J. T. Kemshead Breakdown of academic impact, for papers by Chien‐Tsun Kuan Breakdown of academic impact, for papers by Charles N. Pegram Breakdown of academic impact, for papers by Sandrine Valsesia‐Wittmann Breakdown of academic impact, for papers by Meng-Fen Wu Breakdown of academic impact, for papers by Peisheng Hu
Rankless by CCL
2026